 Shelley Miyamoto
Concepts (372)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 34 | 2023 | 671 | 4.130 |
Why?
| | Heart Defects, Congenital | 14 | 2023 | 703 | 2.900 |
Why?
| | Heart Ventricles | 15 | 2022 | 727 | 2.630 |
Why?
| | Cardiomyopathy, Dilated | 13 | 2021 | 344 | 2.600 |
Why?
| | Heart Failure | 16 | 2023 | 1969 | 1.990 |
Why?
| | MicroRNAs | 8 | 2023 | 637 | 1.980 |
Why?
| | Circulating MicroRNA | 3 | 2023 | 23 | 1.780 |
Why?
| | Cardiomyopathies | 7 | 2023 | 299 | 1.780 |
Why?
| | Myocardium | 8 | 2021 | 970 | 1.590 |
Why?
| | Hypoplastic Left Heart Syndrome | 6 | 2017 | 112 | 1.500 |
Why?
| | Milrinone | 2 | 2021 | 27 | 1.340 |
Why?
| | Ventricular Remodeling | 4 | 2021 | 229 | 1.300 |
Why?
| | Myocytes, Cardiac | 7 | 2021 | 472 | 1.300 |
Why?
| | Cardiomyopathy, Hypertrophic | 3 | 2023 | 119 | 1.080 |
Why?
| | Ventricular Function, Right | 2 | 2018 | 257 | 1.080 |
Why?
| | Heart Diseases | 5 | 2023 | 341 | 1.030 |
Why?
| | Child | 58 | 2023 | 19129 | 0.990 |
Why?
| | Graft Rejection | 8 | 2021 | 555 | 0.950 |
Why?
| | Ventricular Function, Left | 5 | 2018 | 468 | 0.820 |
Why?
| | Infant | 32 | 2022 | 8293 | 0.790 |
Why?
| | Graft Survival | 7 | 2023 | 504 | 0.790 |
Why?
| | Child, Preschool | 36 | 2021 | 9491 | 0.720 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 77 | 0.700 |
Why?
| | Receptors, Adrenergic, beta | 3 | 2016 | 144 | 0.700 |
Why?
| | Phosphodiesterase 3 Inhibitors | 2 | 2016 | 13 | 0.690 |
Why?
| | Fever | 1 | 2020 | 283 | 0.670 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2018 | 22 | 0.660 |
Why?
| | Down-Regulation | 3 | 2021 | 627 | 0.640 |
Why?
| | Steroids | 2 | 2015 | 153 | 0.600 |
Why?
| | Hemodynamics | 6 | 2015 | 1004 | 0.600 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2017 | 146 | 0.570 |
Why?
| | Female | 60 | 2023 | 61565 | 0.550 |
Why?
| | Humans | 80 | 2023 | 118974 | 0.550 |
Why?
| | Male | 55 | 2023 | 57801 | 0.550 |
Why?
| | Fontan Procedure | 4 | 2023 | 154 | 0.550 |
Why?
| | Histone Deacetylases | 1 | 2017 | 198 | 0.540 |
Why?
| | Echocardiography | 6 | 2021 | 556 | 0.500 |
Why?
| | Biomarkers | 9 | 2021 | 3588 | 0.480 |
Why?
| | Case-Control Studies | 8 | 2021 | 3171 | 0.460 |
Why?
| | Adaptation, Physiological | 2 | 2017 | 502 | 0.440 |
Why?
| | Cardiovascular Diseases | 2 | 2022 | 1798 | 0.430 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2012 | 44 | 0.430 |
Why?
| | Waiting Lists | 2 | 2013 | 228 | 0.430 |
Why?
| | Animals, Newborn | 5 | 2021 | 806 | 0.410 |
Why?
| | Phosphoric Diester Hydrolases | 3 | 2016 | 45 | 0.410 |
Why?
| | Recovery of Function | 2 | 2015 | 604 | 0.400 |
Why?
| | Calcium-Binding Proteins | 3 | 2021 | 217 | 0.400 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 3 | 2017 | 29 | 0.400 |
Why?
| | Dexmedetomidine | 3 | 2017 | 52 | 0.390 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 2445 | 0.380 |
Why?
| | Adolescent | 32 | 2023 | 18480 | 0.380 |
Why?
| | Phenotype | 4 | 2023 | 3003 | 0.370 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2010 | 240 | 0.360 |
Why?
| | Age Factors | 9 | 2018 | 2995 | 0.350 |
Why?
| | Primary Graft Dysfunction | 1 | 2009 | 32 | 0.340 |
Why?
| | Cardiolipins | 3 | 2021 | 73 | 0.340 |
Why?
| | Prospective Studies | 11 | 2021 | 6471 | 0.330 |
Why?
| | Adenosine Monophosphate | 2 | 2021 | 51 | 0.330 |
Why?
| | Reoviridae Infections | 1 | 2009 | 55 | 0.330 |
Why?
| | Rats, Sprague-Dawley | 5 | 2021 | 2478 | 0.330 |
Why?
| | Granuloma, Plasma Cell | 1 | 2008 | 11 | 0.330 |
Why?
| | Myocarditis | 1 | 2009 | 95 | 0.310 |
Why?
| | Signal Transduction | 3 | 2017 | 4709 | 0.310 |
Why?
| | Retrospective Studies | 21 | 2021 | 12978 | 0.310 |
Why?
| | Cardiac Catheterization | 4 | 2017 | 541 | 0.300 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2017 | 333 | 0.290 |
Why?
| | Kidney Transplantation | 2 | 2023 | 585 | 0.290 |
Why?
| | Ventricular Outflow Obstruction | 2 | 2022 | 36 | 0.290 |
Why?
| | Databases, Factual | 5 | 2016 | 1231 | 0.290 |
Why?
| | Phosphorylation | 4 | 2021 | 1633 | 0.290 |
Why?
| | Immunosuppressive Agents | 4 | 2023 | 681 | 0.280 |
Why?
| | Calcium | 3 | 2021 | 1169 | 0.270 |
Why?
| | Infant, Newborn | 10 | 2021 | 5255 | 0.270 |
Why?
| | Coronary Artery Disease | 3 | 2018 | 647 | 0.260 |
Why?
| | Adenylyl Cyclases | 2 | 2016 | 86 | 0.260 |
Why?
| | Coronary Vessels | 2 | 2017 | 233 | 0.250 |
Why?
| | Treatment Outcome | 14 | 2021 | 9342 | 0.250 |
Why?
| | Fibrosis | 2 | 2017 | 483 | 0.250 |
Why?
| | Heart-Assist Devices | 4 | 2019 | 485 | 0.240 |
Why?
| | Cardiomyopathy, Restrictive | 1 | 2023 | 10 | 0.230 |
Why?
| | Heart | 3 | 2022 | 631 | 0.230 |
Why?
| | Pulmonary Artery | 1 | 2009 | 1063 | 0.220 |
Why?
| | Sarcomeres | 1 | 2023 | 91 | 0.220 |
Why?
| | Data Accuracy | 1 | 2022 | 56 | 0.220 |
Why?
| | Cyclic AMP | 2 | 2014 | 242 | 0.220 |
Why?
| | Fibroma | 1 | 2022 | 20 | 0.210 |
Why?
| | Transcriptome | 2 | 2021 | 756 | 0.210 |
Why?
| | Heart Neoplasms | 1 | 2022 | 50 | 0.210 |
Why?
| | Barth Syndrome | 1 | 2021 | 9 | 0.210 |
Why?
| | Electron Transport Complex I | 1 | 2021 | 36 | 0.210 |
Why?
| | Longevity | 1 | 2022 | 151 | 0.200 |
Why?
| | Focal Adhesions | 1 | 2021 | 44 | 0.200 |
Why?
| | Cardiopulmonary Bypass | 3 | 2022 | 203 | 0.200 |
Why?
| | Fetofetal Transfusion | 1 | 2021 | 23 | 0.200 |
Why?
| | Amniotic Fluid | 1 | 2021 | 68 | 0.200 |
Why?
| | Cytokines | 1 | 2009 | 1900 | 0.190 |
Why?
| | Heart Rate | 3 | 2023 | 729 | 0.190 |
Why?
| | Calcium Channel Agonists | 1 | 2020 | 10 | 0.190 |
Why?
| | Probenecid | 1 | 2020 | 9 | 0.190 |
Why?
| | Cardiac Output, Low | 1 | 2021 | 68 | 0.190 |
Why?
| | Serum | 2 | 2018 | 63 | 0.190 |
Why?
| | Cells, Cultured | 4 | 2019 | 4077 | 0.190 |
Why?
| | Isoproterenol | 2 | 2018 | 125 | 0.190 |
Why?
| | Cardiotonic Agents | 1 | 2021 | 127 | 0.180 |
Why?
| | Young Adult | 12 | 2023 | 10793 | 0.180 |
Why?
| | Hypertension, Pulmonary | 3 | 2017 | 1794 | 0.180 |
Why?
| | ROC Curve | 3 | 2017 | 473 | 0.180 |
Why?
| | Apoptosis | 1 | 2009 | 2484 | 0.170 |
Why?
| | Atrial Function, Right | 1 | 2019 | 15 | 0.170 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2020 | 128 | 0.170 |
Why?
| | Tissue Donors | 3 | 2016 | 336 | 0.170 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2 | 2021 | 34 | 0.170 |
Why?
| | Troponin I | 1 | 2019 | 83 | 0.170 |
Why?
| | Fatty Acids | 1 | 2021 | 407 | 0.170 |
Why?
| | Phosphodiesterase Inhibitors | 2 | 2016 | 86 | 0.170 |
Why?
| | Mitochondria, Heart | 2 | 2020 | 76 | 0.170 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 239 | 0.160 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2018 | 36 | 0.160 |
Why?
| | Heart Atria | 1 | 2019 | 112 | 0.160 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2013 | 374 | 0.160 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 516 | 0.160 |
Why?
| | Surgical Wound Dehiscence | 1 | 2017 | 19 | 0.160 |
Why?
| | Extracellular Matrix | 1 | 2021 | 446 | 0.160 |
Why?
| | Protein Kinase C beta | 1 | 2017 | 26 | 0.150 |
Why?
| | Patient Transfer | 1 | 2019 | 143 | 0.150 |
Why?
| | Receptors, Adrenergic, alpha-2 | 1 | 2017 | 17 | 0.150 |
Why?
| | Time Factors | 6 | 2018 | 6412 | 0.150 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2016 | 15 | 0.150 |
Why?
| | G-Protein-Coupled Receptor Kinase 2 | 1 | 2016 | 11 | 0.150 |
Why?
| | Death, Sudden, Cardiac | 1 | 2018 | 166 | 0.150 |
Why?
| | Survival Analysis | 4 | 2021 | 1267 | 0.150 |
Why?
| | Transition to Adult Care | 1 | 2017 | 58 | 0.150 |
Why?
| | Galectin 3 | 1 | 2016 | 20 | 0.150 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2016 | 56 | 0.150 |
Why?
| | Animals | 10 | 2021 | 33381 | 0.150 |
Why?
| | Kaplan-Meier Estimate | 3 | 2015 | 842 | 0.150 |
Why?
| | Electrocardiography | 3 | 2015 | 556 | 0.140 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 736 | 0.140 |
Why?
| | Vectorcardiography | 1 | 2016 | 5 | 0.140 |
Why?
| | Specimen Handling | 1 | 2018 | 165 | 0.140 |
Why?
| | Research Design | 1 | 2022 | 969 | 0.140 |
Why?
| | Perioperative Care | 1 | 2017 | 132 | 0.140 |
Why?
| | Genetic Markers | 1 | 2017 | 348 | 0.140 |
Why?
| | Sirolimus | 1 | 2017 | 195 | 0.140 |
Why?
| | Adult | 12 | 2023 | 31512 | 0.140 |
Why?
| | Self Care | 1 | 2019 | 357 | 0.140 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 589 | 0.140 |
Why?
| | Isoenzymes | 1 | 2017 | 297 | 0.140 |
Why?
| | Mutation | 3 | 2023 | 3457 | 0.140 |
Why?
| | Arrhythmias, Cardiac | 1 | 2018 | 277 | 0.140 |
Why?
| | Vascular Resistance | 1 | 2017 | 356 | 0.140 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 290 | 0.140 |
Why?
| | Plasma | 1 | 2018 | 224 | 0.140 |
Why?
| | Exosomes | 1 | 2017 | 92 | 0.140 |
Why?
| | Risk Factors | 9 | 2018 | 9000 | 0.140 |
Why?
| | Vasoconstriction | 1 | 2017 | 213 | 0.140 |
Why?
| | Statistics as Topic | 1 | 2016 | 307 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2018 | 527 | 0.130 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2012 | 79 | 0.130 |
Why?
| | Up-Regulation | 1 | 2018 | 872 | 0.130 |
Why?
| | Surgical Wound Infection | 1 | 2017 | 251 | 0.130 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2015 | 66 | 0.130 |
Why?
| | Exercise Test | 3 | 2023 | 551 | 0.130 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 167 | 0.130 |
Why?
| | Hypnotics and Sedatives | 1 | 2015 | 136 | 0.130 |
Why?
| | Ketamine | 1 | 2015 | 93 | 0.120 |
Why?
| | Stroke Volume | 2 | 2016 | 513 | 0.120 |
Why?
| | Tachycardia, Ventricular | 1 | 2016 | 151 | 0.120 |
Why?
| | Hypoalbuminemia | 1 | 2014 | 27 | 0.120 |
Why?
| | Rats | 4 | 2021 | 5392 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1597 | 0.120 |
Why?
| | Prognosis | 4 | 2015 | 3443 | 0.120 |
Why?
| | Adrenergic beta-1 Receptor Antagonists | 1 | 2013 | 9 | 0.120 |
Why?
| | Propensity Score | 1 | 2015 | 242 | 0.120 |
Why?
| | Growth Disorders | 1 | 2014 | 77 | 0.120 |
Why?
| | Organ Transplantation | 1 | 2016 | 165 | 0.120 |
Why?
| | Anthracyclines | 1 | 2013 | 41 | 0.120 |
Why?
| | Coronary Angiography | 1 | 2016 | 311 | 0.120 |
Why?
| | Patient Compliance | 1 | 2017 | 537 | 0.120 |
Why?
| | Fetal Heart | 1 | 2013 | 29 | 0.120 |
Why?
| | Vascular Diseases | 1 | 2016 | 241 | 0.110 |
Why?
| | Tissue and Organ Procurement | 1 | 2016 | 248 | 0.110 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 43 | 0.110 |
Why?
| | Patient Education as Topic | 1 | 2017 | 699 | 0.110 |
Why?
| | Connexin 43 | 1 | 2012 | 23 | 0.110 |
Why?
| | Myosin Heavy Chains | 1 | 2014 | 192 | 0.110 |
Why?
| | Interleukin-1 | 1 | 2016 | 980 | 0.110 |
Why?
| | Heart Arrest | 1 | 2015 | 291 | 0.100 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2014 | 159 | 0.100 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2012 | 106 | 0.100 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2012 | 175 | 0.100 |
Why?
| | Altitude | 2 | 2021 | 422 | 0.100 |
Why?
| | American Heart Association | 2 | 2023 | 270 | 0.100 |
Why?
| | Follow-Up Studies | 6 | 2021 | 4596 | 0.100 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2014 | 228 | 0.100 |
Why?
| | Incidence | 2 | 2015 | 2424 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2010 | 64 | 0.090 |
Why?
| | Lymphoproliferative Disorders | 1 | 2010 | 46 | 0.090 |
Why?
| | Pulmonary Embolism | 1 | 2012 | 183 | 0.090 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 238 | 0.090 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 208 | 0.090 |
Why?
| | Mycoses | 1 | 2010 | 69 | 0.090 |
Why?
| | RNA | 1 | 2016 | 833 | 0.090 |
Why?
| | Disease Management | 1 | 2014 | 571 | 0.090 |
Why?
| | Patient Selection | 1 | 2014 | 676 | 0.090 |
Why?
| | Air Ambulances | 1 | 2010 | 32 | 0.090 |
Why?
| | Transplantation Conditioning | 1 | 2010 | 156 | 0.090 |
Why?
| | Oxygen Consumption | 2 | 2023 | 586 | 0.090 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1323 | 0.090 |
Why?
| | Colorado | 6 | 2017 | 4196 | 0.090 |
Why?
| | Thrombophilia | 1 | 2009 | 68 | 0.090 |
Why?
| | Transplantation, Homologous | 3 | 2021 | 415 | 0.090 |
Why?
| | Cardiac Surgical Procedures | 2 | 2017 | 461 | 0.090 |
Why?
| | Cohort Studies | 6 | 2015 | 5116 | 0.090 |
Why?
| | Travel | 1 | 2010 | 116 | 0.090 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1185 | 0.090 |
Why?
| | Mitral Valve Stenosis | 1 | 2008 | 21 | 0.080 |
Why?
| | Registries | 2 | 2014 | 1810 | 0.080 |
Why?
| | Cytomegalovirus Infections | 1 | 2010 | 187 | 0.080 |
Why?
| | Angioplasty, Balloon | 1 | 2009 | 88 | 0.080 |
Why?
| | RNA, Transfer, Glu | 1 | 2007 | 5 | 0.080 |
Why?
| | Reoperation | 3 | 2021 | 557 | 0.080 |
Why?
| | United States | 7 | 2022 | 12555 | 0.080 |
Why?
| | RNA, Messenger | 3 | 2021 | 2657 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1440 | 0.080 |
Why?
| | Oxidation-Reduction | 2 | 2021 | 940 | 0.070 |
Why?
| | Mitochondrial Diseases | 1 | 2007 | 79 | 0.070 |
Why?
| | Pregnancy | 2 | 2021 | 5691 | 0.070 |
Why?
| | Stem Cells | 1 | 2010 | 559 | 0.070 |
Why?
| | Brain Ischemia | 1 | 2009 | 310 | 0.070 |
Why?
| | Myocardial Contraction | 2 | 2019 | 339 | 0.070 |
Why?
| | Stents | 1 | 2009 | 457 | 0.070 |
Why?
| | Stroke | 1 | 2012 | 1047 | 0.060 |
Why?
| | Pilot Projects | 2 | 2019 | 1419 | 0.060 |
Why?
| | Middle Aged | 4 | 2016 | 27617 | 0.060 |
Why?
| | Polymerase Chain Reaction | 2 | 2017 | 1012 | 0.060 |
Why?
| | Risk | 2 | 2019 | 853 | 0.060 |
Why?
| | Palliative Care | 1 | 2009 | 629 | 0.060 |
Why?
| | Everolimus | 1 | 2023 | 64 | 0.060 |
Why?
| | Blotting, Western | 2 | 2016 | 1194 | 0.060 |
Why?
| | Mycophenolic Acid | 1 | 2023 | 79 | 0.050 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2674 | 0.050 |
Why?
| | Endopeptidase K | 1 | 2021 | 14 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2015 | 770 | 0.050 |
Why?
| | Tacrolimus | 1 | 2023 | 151 | 0.050 |
Why?
| | Ribonucleases | 1 | 2021 | 53 | 0.050 |
Why?
| | Acyltransferases | 1 | 2021 | 53 | 0.050 |
Why?
| | Light Coagulation | 1 | 2021 | 7 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2023 | 233 | 0.050 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2022 | 75 | 0.050 |
Why?
| | Fetoscopy | 1 | 2021 | 29 | 0.050 |
Why?
| | Serum Response Factor | 1 | 2021 | 31 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2016 | 1795 | 0.050 |
Why?
| | Microscopy, Atomic Force | 1 | 2021 | 118 | 0.050 |
Why?
| | Genotype | 2 | 2017 | 1882 | 0.050 |
Why?
| | Drainage | 1 | 2021 | 157 | 0.050 |
Why?
| | TRPV Cation Channels | 1 | 2020 | 32 | 0.050 |
Why?
| | Gene Expression | 2 | 2017 | 1489 | 0.050 |
Why?
| | Glomerular Filtration Rate | 1 | 2023 | 683 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2014 | 1474 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2023 | 965 | 0.050 |
Why?
| | Postoperative Complications | 3 | 2021 | 2235 | 0.040 |
Why?
| | Recurrence | 2 | 2012 | 975 | 0.040 |
Why?
| | Ultrasonography, Prenatal | 1 | 2021 | 227 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 481 | 0.040 |
Why?
| | Resource Allocation | 1 | 2019 | 38 | 0.040 |
Why?
| | Exercise Therapy | 1 | 2023 | 355 | 0.040 |
Why?
| | Neoplasms | 1 | 2013 | 2179 | 0.040 |
Why?
| | Inflammation | 1 | 2009 | 2566 | 0.040 |
Why?
| | Ventricular Function | 1 | 2019 | 60 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2021 | 404 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 625 | 0.040 |
Why?
| | Risk Assessment | 3 | 2016 | 3057 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 409 | 0.040 |
Why?
| | Flecainide | 1 | 2018 | 7 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2020 | 187 | 0.040 |
Why?
| | Treatment Failure | 2 | 2010 | 341 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2017 | 2062 | 0.040 |
Why?
| | Guinea Pigs | 1 | 2018 | 151 | 0.040 |
Why?
| | Ryanodine Receptor Calcium Release Channel | 1 | 2018 | 59 | 0.040 |
Why?
| | Administration, Oral | 1 | 2020 | 756 | 0.040 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2018 | 113 | 0.040 |
Why?
| | Freezing | 1 | 2018 | 87 | 0.040 |
Why?
| | Adenoidectomy | 1 | 2017 | 60 | 0.040 |
Why?
| | Cell Size | 1 | 2017 | 86 | 0.040 |
Why?
| | Atrial Natriuretic Factor | 1 | 2016 | 59 | 0.040 |
Why?
| | Sampling Studies | 1 | 2016 | 92 | 0.040 |
Why?
| | Observer Variation | 1 | 2017 | 309 | 0.040 |
Why?
| | Homeostasis | 1 | 2020 | 594 | 0.040 |
Why?
| | Renin-Angiotensin System | 1 | 2017 | 82 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2019 | 749 | 0.040 |
Why?
| | Tonsillectomy | 1 | 2017 | 78 | 0.040 |
Why?
| | Brain Death | 1 | 2016 | 29 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2018 | 3730 | 0.040 |
Why?
| | Kidney | 1 | 2023 | 1353 | 0.030 |
Why?
| | Autopsy | 1 | 2016 | 89 | 0.030 |
Why?
| | Mitochondria | 1 | 2021 | 786 | 0.030 |
Why?
| | Sympathetic Nervous System | 1 | 2017 | 171 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2017 | 153 | 0.030 |
Why?
| | Hot Temperature | 1 | 2018 | 334 | 0.030 |
Why?
| | Diastole | 1 | 2016 | 145 | 0.030 |
Why?
| | Systole | 1 | 2016 | 168 | 0.030 |
Why?
| | Self-Management | 1 | 2017 | 136 | 0.030 |
Why?
| | Italy | 1 | 2015 | 90 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2707 | 0.030 |
Why?
| | Cardiac Output | 1 | 2015 | 147 | 0.030 |
Why?
| | Markov Chains | 1 | 2015 | 118 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2019 | 726 | 0.030 |
Why?
| | DNA, Complementary | 1 | 2015 | 268 | 0.030 |
Why?
| | Action Potentials | 1 | 2018 | 420 | 0.030 |
Why?
| | Reference Values | 1 | 2016 | 774 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2015 | 99 | 0.030 |
Why?
| | Public Health | 1 | 2019 | 450 | 0.030 |
Why?
| | Orthopedic Procedures | 1 | 2017 | 225 | 0.030 |
Why?
| | Exons | 1 | 2015 | 307 | 0.030 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2017 | 185 | 0.030 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2014 | 37 | 0.030 |
Why?
| | Analgesics | 1 | 2015 | 159 | 0.030 |
Why?
| | Linear Models | 1 | 2016 | 827 | 0.030 |
Why?
| | Drug Therapy | 1 | 2014 | 76 | 0.030 |
Why?
| | Self Report | 1 | 2017 | 699 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1355 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2016 | 1293 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 996 | 0.030 |
Why?
| | Program Evaluation | 1 | 2017 | 845 | 0.030 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2013 | 114 | 0.030 |
Why?
| | Exercise | 1 | 2023 | 1657 | 0.030 |
Why?
| | Mice | 3 | 2015 | 15520 | 0.030 |
Why?
| | Transplant Recipients | 1 | 2014 | 148 | 0.030 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 226 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 827 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2013 | 253 | 0.030 |
Why?
| | Heart Function Tests | 1 | 2012 | 61 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1384 | 0.030 |
Why?
| | Pediatrics | 1 | 2019 | 985 | 0.030 |
Why?
| | Nutritional Status | 1 | 2014 | 300 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 1868 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1125 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2513 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2010 | 250 | 0.020 |
Why?
| | Mass Screening | 1 | 2017 | 1052 | 0.020 |
Why?
| | France | 1 | 2010 | 35 | 0.020 |
Why?
| | Factor VIII | 1 | 2009 | 56 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 294 | 0.020 |
Why?
| | Shock, Cardiogenic | 1 | 2010 | 53 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2010 | 273 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2010 | 244 | 0.020 |
Why?
| | Body Weight | 1 | 2014 | 934 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 1720 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 525 | 0.020 |
Why?
| | Adaptive Immunity | 1 | 2010 | 161 | 0.020 |
Why?
| | Internationality | 1 | 2010 | 152 | 0.020 |
Why?
| | Tricuspid Atresia | 1 | 2008 | 7 | 0.020 |
Why?
| | Venae Cavae | 1 | 2008 | 10 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 1945 | 0.020 |
Why?
| | Vena Cava, Superior | 1 | 2008 | 21 | 0.020 |
Why?
| | Device Removal | 1 | 2009 | 127 | 0.020 |
Why?
| | Anastomosis, Surgical | 1 | 2008 | 146 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 467 | 0.020 |
Why?
| | Anticoagulants | 1 | 2012 | 559 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1079 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2010 | 1206 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 360 | 0.020 |
Why?
| | Probability | 1 | 2008 | 305 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2015 | 2874 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2007 | 287 | 0.020 |
Why?
| | Pulmonary Circulation | 1 | 2008 | 424 | 0.020 |
Why?
| | Aged | 2 | 2014 | 19657 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 4708 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2008 | 1166 | 0.020 |
Why?
| | Length of Stay | 1 | 2008 | 1032 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2010 | 1774 | 0.010 |
Why?
|
|
Miyamoto's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|